Jounce Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Jounce Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 4 completed early-phase tilt upper quartile by trial count

Jounce Therapeutics: 5 sponsored US clinical trials, none currently recruiting.

Jounce Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 1 trials.

Upper-quartile sponsor footprint

Jounce Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

COMPLETED Phase 1

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

NCT04669899
TERMINATED Phase 1

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

NCT04319224
COMPLETED Phase 2

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

NCT03989362
COMPLETED Phase 1

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

NCT03790488
COMPLETED Phase 1

JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

NCT02904226

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1

Therapeutic Areas

Cancer 1

How the Jounce Therapeutics early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 4 completed (80%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Cancer (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Jounce Therapeutics: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Jounce Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Jounce Therapeutics4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Jounce Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Jounce Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Jounce Therapeutics page

5 registered trials is a research-attention snapshot, not an endorsement of Jounce Therapeutics or any single study.

  • None of Jounce Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Cancer is the condition Jounce Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jounce Therapeutics pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.